Disability and Psychological Symptoms After Injection or Conservative Care for Lumbar Disc Herniation
NCT07930156, Completed, Hebei Medical University Third Hospital
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Disability and Psychological Symptoms After Injection or Conservative Care for Lumbar Disc Herniation | ClinicalTrials.gov |
| NCT number | NCT07930156 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 64 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Hebei Medical University Third Hospital | ClinicalTrials.gov |
| Conditions | Lumbar Disc Herniation, Lumbar Radiculopathy | ClinicalTrials.gov |
| Interventions | Fluoroscopy-guided periradicular/epidural injection with reverse geometric planning, Lidocaine, Compound betamethasone, Celecoxib, Infrared physical therapy, Home rehabilitation guidance | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Oswestry Disability Index score at 3 months | 3 months after initial treatment | Total Oswestry Disability Index (ODI) score at the nominal three-month follow-up, recorded as a percentage from 0 to 100; higher scores indicate greater disability. The registered metric is the absolute three-month total score. Baseline ODI was recorded for adjustment. Only final percentages were retained; item-level scores and the original scoring denominator were unavailable. The primary-outcome designation was assigned after data collection. | ClinicalTrials.gov |
| Secondary | Patient Health Questionnaire-9 score at 3 months | 3 months after initial treatment | Total Patient Health Questionnaire-9 (PHQ-9) score at the nominal three-month follow-up, ranging from 0 to 27; higher scores indicate greater depressive symptom burden. The registered metric is the absolute three-month total score. Baseline PHQ-9 was recorded for adjustment. Total scores do not establish a psychiatric diagnosis or remission. The secondary-outcome designation was assigned after data collection. | ClinicalTrials.gov |
| Secondary | Generalized Anxiety Disorder-7 score at 3 months | 3 months after initial treatment | Total Generalized Anxiety Disorder-7 (GAD-7) score at the nominal three-month follow-up, ranging from 0 to 21; higher scores indicate greater anxiety symptom burden. The registered metric is the absolute three-month total score. Baseline GAD-7 was recorded for adjustment. Total scores do not establish a psychiatric diagnosis or remission. The secondary-outcome designation was assigned after data collection. | ClinicalTrials.gov |
| Other | Immediate visual analog scale pain score | Immediately after the initial injection or initial conservative-care session | Self-rated pain score on a 0 to 10 visual analog scale (VAS), with 0 indicating no pain and 10 the worst pain imaginable. The registered metric is the absolute immediate post-treatment total score. Pretreatment pain was also recorded as a reference. Immediate ratings followed the injection or the first conservative-care session and were descriptive. Exact elapsed minutes were unavailable. Pain was not measured at three months. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)